Voronoi Inc 310210
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- KRW 31,000.00
- Day Range
- KRW 30,400.00–31,200.00
- 52-Week Range
- —–—
- Bid/Ask
- KRW 31,150.00 / KRW 31,200.00
- Market Cap
- KRW 522.56 Bil
- Volume/Avg
- 5,018 / 127,135
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 730.35
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Voronoi Inc is a biotech company that develops novel kinase inhibitors and targets protein degraders.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 114
- Website
- https://www.voronoi.io
Comparables
Valuation
|
Metric
|
310210
|
323990
|
052020
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 7.81 | 4.52 | 8.97 |
Price/Sales | 730.35 | — | 53.03 |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
310210
|
323990
|
052020
|
|---|---|---|---|
Quick Ratio | 4.85 | 54.78 | 8.87 |
Current Ratio | 4.91 | 55.43 | 9.33 |
Interest Coverage | −18.54 | −260.75 | −270.58 |
Quick Ratio
310210
323990
052020
Profitability
|
Metric
|
310210
|
323990
|
052020
|
|---|---|---|---|
Return on Assets (Normalized) | −42.78% | −29.47% | −43.51% |
Return on Equity (Normalized) | −96.10% | −30.90% | −54.60% |
Return on Invested Capital (Normalized) | −44.97% | −33.70% | −54.02% |
Return on Assets
310210
323990
052020
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Gcnhlzfhtf | Dhvh | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Whhwrbrkw | Qjffxh | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Czhyhhs | Lxjybjs | $97.3 Bil | |
MRNA
| Moderna Inc | Kzvnryd | Xlms | $41.3 Bil | |
ARGX
| argenx SE ADR | Krwkwspn | Mwm | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Rgqyghtx | Mdl | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Nzmcwmb | Xgxdg | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Zjqscvnd | Xtsfpr | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Rqphzphtzr | Ydbgmn | $12.6 Bil | |
INCY
| Incyte Corp | Jhsnrqmfw | Tkfkds | $11.6 Bil |